Close Menu

NEW YORK – Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, and OraSure Technologies subsidiary CoreBiome said on Tuesday that they are collaborating to develop a colon cancer screening test.

The test, called LifeKit Prevent, will use microbial biomarkers to predict the development of precancerous adenomas and carcinomas. The companies said they will use shotgun metagenomic sequencing, machine learning, and AI-driven microbiome analytics to accelerate their development pipeline. 

Financial terms of the collaboration were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.